Regulation of glucose utilization in tumors by a stress-modified insulin: anti-insulin system.

M. Woods,J. Hunter,D. Burk

DOI: https://doi.org/10.1093/JNCI/16.2.351

1955-10-01

Journal of the National Cancer Institute

Abstract:

What problem does this paper attempt to address?

[The Clinical Significance of Hematological Damage in Systemic Lupus Erythematosus and Related Antibodies].

Xiao-ying Zhao,Ping Zhang,Lian-sheng Huang,Xiao-hong Zhang

DOI: https://doi.org/10.3760/j.issn:0578-1426.2006.05.007

2006-01-01

Abstract:OBJECTIVETo investigate the incidence of hematological damage in systemic lupus erythematosus (SLE) and its relationship with disease state and immunological parameters of SLE.METHODS155 inpatients with SLE were enrolled in this retrospective study in our hospital. All patients fulfilled the criteria of SLE drawn up by American Rheumatism Association (ARA) in 1982. Fasting blood samples were obtained and blood routine, liver and renal function, immunological parameters were determined. According to SLE Disease Activity Index (SLEDAI), disease state was evaluated in 155 patients and their correlation parameters were analyzed, with hematological damage and immunological parameters analyzed.RESULTS67.7% of the patients had hematological disorder. Single cell line damage was present in 32.9% of the patients, while 34.8% of the patients were involved in damage of several cell lines. The detectable rate of Anti-Sm (43.8%) and Anti-RNP (64.8%) in patients with hematological disorder were higher than those in patients without hematological disorder (Anti-Sm 26.0%, Anti-RNP 44.0%). The positive rate of Anti-RNP were 69.0% in patients with red cell line damage while only 44.0% in patients without hematological disorder (P < 0.05). There was no significant difference in Anti-RNP between patients without hematological disorder and patients with leukocytopenia or thrombocytopenia. Among the 155 patients 49 were in progressive stage and 106 in stationary stage. Hematological damage occurred approximately in 75.5% of the patients in progressive stage and in 64.2% of the patients in stationary stage. The prevalences of Anti-dsDNA, Anti-RNP, Anti-Sm and several cell lines damage were significantly higher in patients with progressive stage than in patients with stationary stage.CONCLUSIONSHematological system is easily damaged in patients with SLE and its involvement is related with the disease state. Anti-RNP could reflect red cell line damage.
Non-simple genus minimizers in lens spaces

J. Greene,Yi Ni

2013-05-02

Abstract:Given a one-dimensional homology class in a lens space, a question related to the Berge conjecture on lens space surgeries is to determine all knots realizing the minimal rational genus of all knots in this homology class. It is known that simple knots are rational genus minimizers. In this paper, we construct many non-simple genus minimizers. This negatively answers a question of Rasmussen.
Patients with neuropsychiatric involvement systemic lupus erythematosus experience poorer health-related quality of life and more fatigue than systemic lupus erythematosus patients with no neuropsychiatric involvement, irrespective of neuropsychiatric activity

Dionysis Nikolopoulos,Nursen Cetrez,Julius Lindblom,Leonardo Palazzo,Yvonne Enman,Ioannis Parodis

DOI: https://doi.org/10.1093/rheumatology/keae216

2024-04-05

Rheumatology

Abstract:Abstract Objectives Substantial proportions of patients with systemic lupus erythematosus (SLE) report poor health-related quality of life (HRQoL). Our objective was to investigate the impact of neuropsychiatric involvement (NP) in SLE on patient-reported outcomes. Methods We analysed data from four phase III trials (BLISS-52, BLISS-76, BLISS-SC, EMBRACE; N = 2968). The neuropsychiatric SLE (NPSLE) group comprised individuals with NP-British Isles Lupus Assessment group (BILAG) A/B/C/D or score in any descriptor of the NP-SLEDAI-2K at baseline (N = 350), while the non-NPSLE group consisted of patients with NP-BILAG E (N = 2618). HRQoL was assessed with the SF-36, EQ-5D-3L, and FACIT-F. Full health state (FHS) was defined as “no problems” in all EQ-5D dimensions. Results NPSLE patients reported lower scores in the SF-36 physical and mental component summary compared with the non-NPSLE population (mean±s.d.: 35.7±9.1 versus 39.6±9.6; p<0.001 and 37.3±12.1 versus 41.4±11.0; p<0.001, respectively). NPSLE patients also exhibited impaired HRQoL in all EQ-5D dimensions compared with non-NPSLE patients (p<0.05 for all). A substantially lower proportion among NPSLE patients experienced FHS in comparison with the non-NPSLE group (3.3% versus 14.5%; p<0.001). NPSLE was associated with severe fatigue (23.8±12.2 versus 31.5±11.6; p<0.001). Notably, our findings revealed no discernible distinctions between active and inactive NPSLE patients with regard to SF-36, EQ-5D, FHS, and FACIT-F scores. Conclusion Neuropsychiatric involvement in patients with SLE has a detrimental effect on HRQoL experience and is associated with severe fatigue, regardless of the degree of neuropsychiatric disease activity. Early intervention is warranted in NPSLE patients to enhance long-term HRQoL experience.

rheumatology
Prospective Study of Neuropsychiatric Events in Systemic Lupus Erythematosus

JOHN G. HANLY,LI SU,VERN FAREWELL,GRACE McCURDY,LISA FOUGERE,KARA THOMPSON

DOI: https://doi.org/10.3899/jrheum.081133

2009-05-15

The Journal of Rheumatology

Abstract:Objective. To prospectively examine neuropsychiatric (NP) events and their association with health related quality of life (HRQOL) over time in patients with systemic lupus erythematosus (SLE). Methods. In an observational cohort study from a single academic center, NP events and their attribution were identified at enrollment and at annual assessments for up to 7 years. NP events were characterized using the American College of Rheumatology case definitions; other variables were global SLE disease activity and cumulative organ damage. The outcomes of NP events were recorded and self-report HRQOL was measured with the mental (MCS) and physical (PCS) component summary scores of the Medical Outcomes Study Short Form-36. Results. There were 209 patients, 88% female and 92% Caucasian, with a mean (standard deviation) age of 43.7 (13.8) years. Followup was available in 175/209 (84%) patients. There were 299 NP events in 132/209 (63%) patients over a mean followup of 3.6 (2.5) years. Thirty-one percent of NP events in 54 patients were attributed to SLE. Multivariate analysis indicated lower MCS scores in patients with NP events compared to those without events (p < 0.001) regardless of attribution. The group means for PCS scores were significantly lower in patients with NP events (p < 0.001) regardless of attribution. There was no association between HRQOL and cumulative organ damage, nor between NP events and the progression of organ damage. Conclusion. The association of lower HRQOL with NP events over time, which is independent of progression in cumulative organ damage, emphasizes the persistent negative effect of NP events in the lives of patients with SLE.
Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study

John G. Hanly,Qiuju Li,Li Su,Murray B. Urowitz,Caroline Gordon,Sang‐Cheol Bae,Juanita Romero‐Diaz,Jorge Sanchez‐Guerrero,Sasha Bernatsky,Ann E. Clarke,Daniel J. Wallace,David A. Isenberg,Anisur Rahman,Joan T. Merrill,Paul R. Fortin,Dafna D. Gladman,Ian N. Bruce,Michelle Petri,Ellen M. Ginzler,M. A. Dooley,Kristjan Steinsson,Rosalind Ramsey‐Goldman,Asad A. Zoma,Susan Manzi,Ola Nived,Andreas Jonsen,Munther A. Khamashta,Graciela S. Alarcón,Elisabet Svenungsson,Ronald F. Vollenhoven,Cynthia Aranow,Meggan Mackay,Guillermo Ruiz‐Irastorza,Manuel Ramos‐Casals,S. Sam Lim,Murat Inanc,Kenneth C. Kalunian,Soren Jacobsen,Christine A. Peschken,Diane L. Kamen,Anca Askanase,Chris Theriault,Vernon Farewell

DOI: https://doi.org/10.1002/art.41070

2019-11-28

Abstract:<h3 class="article-section__sub-title section1"> Objectives</h3><p>In a multi‐ethnic/racial, prospective SLE inception cohort, to determine the frequency, clinical characteristics, associations and outcomes in different types of peripheral nervous system (PNS) disease.</p><h3 class="article-section__sub-title section1"> Methods</h3><p>Patients were evaluated annually for 19 neuropsychiatric (NP) events including seven types of PNS disease. SLE disease activity, organ damage, autoantibodies, patient and physician assessment of outcome were measured. Time to event and linear regressions were used as appropriate.</p><h3 class="article-section__sub-title section1"> Results</h3><p>Of 1,827 SLE patients, 88.8% were female, 48.8% Caucasian. The mean±SD age was 35.1±13.3 years, disease duration at enrollment 5.6±4.2 months and follow‐up 7.6±4.6 years. There were 161 PNS events in 139/1,827 (7.6%) patients. The predominant events were peripheral neuropathy [66/161 (41.0%)], mononeuropathy [44/161 (27.3%)] and cranial neuropathy [39/161 (24.2%)] and the majority were attributed to SLE. Multivariate Cox regressions suggested longer time to resolution in patients with prior history of neuropathy, older age at SLE diagnosis, higher SLEDAI‐2K scores, and for peripheral neuropathy versus other neuropathies. Neuropathy was associated with significantly lower SF‐36 physical and mental component summary scores versus patients without NP events. By physician assessment, the majority of neuropathies resolved or improved over time and this was associated with improvements in SF‐36 summary scores for peripheral neuropathy and mononeuropathy.</p><h3 class="article-section__sub-title section1"> Conclusion</h3><p>PNS disease is an important component of total NPSLE and has a significant negative impact on health related quality of life. The outcome is favourable for most patients, but we noted several factors associated with longer time to resolution.</p><p>This article is protected by copyright. All rights reserved.</p>

rheumatology
THU0036 Discriminating Central Nervous System Infection and Neuropsychiatric Involvement in Patients with Systemic Lupus Erythematosus: A Single-Center Experience

J. Chen,X. Feng,H. Wang,B. Hua,L. Sun

DOI: https://doi.org/10.1136/annrheumdis-2014-eular.2205

IF: 27.973

2014-01-01

Annals of the Rheumatic Diseases

Abstract:Background Despite the improvement of survival rates in SLE patients over the past decades, patients still have higher mortalities compared with the general population that can be largely attributed to uncontrolled disease activities and, most importantly, various kinds of severe infections. Objectives The aim of this study is to identify the clinical differences between central nervous system (CNS) infection and neuropsychiatric lupus (NPSLE) in patients with systemic lupus erythematosus (SLE). Methods Clinical manifestations, laboratory test results and prognoses of 14 SLE patients complicated with various CNS infections, hospitalized in the Drum Tower Hospital in the past seven years, were reviewed and compared with those of 34 concomitantly treated NPSLE patients. The sensitivity and specificity for each variable to identify CNS infection was assessed by receiver operating characteristic (ROC) curves. Results Our study shows that mortality rate was much higher in SLE patients with CNS infection than in NPSLE patients. Compared to NPSLE, those with CNS infection had lower lupus disease activity (SLEDAI), but took higher doses of corticosteroids one month before the occurrence of CNS symptoms. Headache, high fever and vomiting were more common in patients with CNS infections, accompanied with the elevation of C-reactive protein level. Cerebrospinal fluid examination (CSF) examination showed increased leukocytes and protein level but decreased glucose level in patients with CNS infections. Of all the variables, the combination of abnormal CSF test, low SLEDAI score, high fever and high intake of prednisone could best discriminate CNS infection from NPSLE in SLE patients (AUC=0.999, p=4.48x10–19). Conclusions We conclude that for SLE patients who have CNS symptoms, low SLE disease activity but high intake of corticosteroids, together with abnormal CSF and high fever, may suggest the existence of CNS infection. Disclosure of Interest : None declared DOI 10.1136/annrheumdis-2014-eular.2205
Neuropsychiatric manifestations in patients with systemic lupus erythematosus: epidemiology and radiology pointing to an immune-mediated cause

Gerda M Steup-Beekman,Elisabeth J M Zirkzee,Danielle Cohen,Bastiaan M A Gahrmann,Bart J Emmer,Stefan C A Steens,Eduard L E M Bollen,Mark A van Buchem,Tom W J Huizinga

DOI: https://doi.org/10.1136/annrheumdis-2012-202369

IF: 27.973

2012-12-19

Annals of the Rheumatic Diseases

Abstract:BACKGROUND: Different pathogenetic pathways have been proposed for neuropsychiatric (NP) manifestations in systemic lupus erythematosus (SLE).OBJECTIVE: To describe the patient characteristics of a large cohort of patients with SLE with NP manifestations (NPSLE) in a single centre and to review whether these and other data are compatible with immune-mediated mechanisms.METHODS: A total of 212 patients were identified from MRI scans of the brain ordered for suspected NPSLE. Data were collected from the medical records. NP syndromes were classified according to the American College of Rheumatology (ACR) nomenclature and case definitions.RESULTS: 155 patients fulfilled the criteria for SLE. In 102 patients NP manifestations were attributed to SLE itself (primary NPSLE) whereas, in the remaining patients, the NP symptoms were due to other causes. The median age at the time of SLE diagnosis in patients with primary NPSLE was 27.5 years and the median duration prior to NPSLE was 2.8 years. Forty patients (39%) had a NP manifestation in the first year of the disease. Cerebrovascular disease, cognitive dysfunction, seizures and headache were the most prevalent syndromes. In 47% of patients with primary NPSLE the MRI scan of the brain showed no abnormalities.CONCLUSIONS: Most NP manifestations in SLE occur early in the disease. This finding, as well as data from quantitative imaging studies and recent pathological studies, point to an immune-mediated pathogenesis.

rheumatology
Therapeutic Strategies and Outcomes in Neuropsychiatric Systemic Lupus Erythematosus: An International Multicenter Retrospective Study

Alessandra Bortoluzzi,Antonis Fanouriakis,Ettore Silvagni,Simone Appenzeller,Linda Carli,Greta Carrara,Alberto Cauli,Fabrizio Conti,Lilian Teresa Lavras Costallat,Ginevra De Marchi,Andrea Doria,Micaela Fredi,Franco Franceschini,Carlo Garaffoni,John G Hanly,Marta Mosca,Elana Murphy,Matteo Piga,Luca Quartuccio,Carlo Alberto Scirè,Paola Tomietto,Simona Truglia,Anna Zanetti,Margherita Zen,George Bertsias,Marcello Govoni

DOI: https://doi.org/10.1093/rheumatology/keae119

2024-02-24

Rheumatology

Abstract:Abstract Objectives The management of neuropsychiatric systemic lupus erythematosus (NPSLE) poses considerable challenges due to limited clinical trials. Therapeutic decisions are customized based on suspected pathogenic mechanisms and symptom severity. This study aimed to investigate therapeutic strategies and disease outcome for patients with NPSLE experiencing their first neuropsychiatric (NP) manifestation. Methods This retrospective cohort study defined NP events according to the American College of Rheumatology case definition, categorizing them into three clusters: central/diffuse, central/focal and peripheral. Clinical judgment and a validated attribution algorithm were used for NP event attribution. Data included demographic variables, SLE disease activity index, cumulative organ damage, and NP manifestation treatments. The clinical outcome of all NP events was determined by a physician seven-point Likert scale. Predictors of clinical improvement/resolution were investigated in a multivariable logistic regression analysis. Results The analysis included 350 events. Immunosuppressants and corticosteroids were more frequently initiated/escalated for SLE-attributed central diffuse or focal NP manifestations. At 12 months of follow-up, 64% of patients showed a clinical improvement in NP manifestations. Focal central events and SLE-attributed manifestations correlated with higher rates of clinical improvement. Patients with NP manifestations attributed to SLE according to clinical judgment and treated with immunosuppressants had a significantly higher probability of achieving clinical response (OR 2.55, 95%CI 1.06–6.41, p= 0.04). Age at diagnosis and focal central events emerged as additional response predictors. Conclusion NP manifestations attributed to SLE by clinical judgment and treated with immunosuppressants demonstrated improved 12-month outcomes. This underscores the importance of accurate attribution and timely diagnosis of NPSLE.

rheumatology
Prevalence, outcome and prognostic factors of neuropsychiatric systemic lupus erythematosus: A real world single center study

Xue Li,Xiaohong Xiang,Jingjing Sun,Shanshan Liu,Ying Liu,Lianghua Feng,Chun Li,Zhanguo Li

DOI: https://doi.org/10.1080/14397595.2019.1589912

2020-01-01

Modern Rheumatology

Abstract:Objectives: To investigate the prevalence, outcome and prognostic factors of neuropsychiatric systemic lupus erythematosus (NPSLE). Methods: SLE inpatients from 2005 to 2016 were included. Information on survival duration and causes of death was collected. Data were analyzed using Kaplan–Meier curves, log-rank tests and Cox proportional hazards modeling. Results: Among 1589 SLE patients, 101 (6.4%) were diagnosed with NPSLE. The overall survival rates of the NPSLE patients were 89%, 85% and 84% at 1, 3 and 5 years, respectively. The standardized mortality ratio of NPSLE patients was 11.14. The most common cause of death was NPSLE related conditions (7, 47%), including intracranial hypertension syndrome, cerebrovascular disease and motor neuron disease. The following variables were associated with death: cardiac involvement, renal involvement, diffuse NPSLE, acute confusional state, more than one NPSLE manifestation, low lymphocyte count, elevated C-reactive protein, abnormal cerebrospinal fluid (CSF) and high systemic lupus erythematosus disease activity index. Acute confusional state (p =.001), elevated intracranial pressure (p =.010) and C-reactive protein (CRP) (p =.032) were independently predictive factors of death. Conclusion: Our study demonstrates an 11.14-fold increased mortality of NPSLE patients compared with general population. NPSLE related disorders are main causes of death. Acute confusional state is the most significant predictive factor for poor prognosis. © 2019, © 2019 Japan College of Rheumatology.
Neuropsychiatric Systemic Lupus Erythematosus: Molecules Involved in Its Imunopathogenesis, Clinical Features, and Treatment

Angel A. Justiz-Vaillant,Darren Gopaul,Sachin Soodeen,Rodolfo Arozarena-Fundora,Odette Arozarena Barbosa,Chandrashehkar Unakal,Reinand Thompson,Bijay Pandit,Srikanth Umakanthan,Patrick E. Akpaka

DOI: https://doi.org/10.3390/molecules29040747

IF: 4.6

2024-02-06

Molecules

Abstract:Systemic lupus erythematosus (SLE) is an idiopathic chronic autoimmune disease that can affect any organ in the body, including the neurological system. Multiple factors, such as environmental (infections), genetic (many HLA alleles including DR2 and DR3, and genes including C4), and immunological influences on self-antigens, such as nuclear antigens, lead to the formation of multiple autoantibodies that cause deleterious damage to bodily tissues and organs. The production of autoantibodies, such as anti-dsDNA, anti-SS(A), anti-SS(B), anti-Smith, and anti-neuronal DNA are characteristic features of this disease. This autoimmune disease results from a failure of the mechanisms responsible for maintaining self-tolerance in T cells, B cells, or both. Immune complexes, circulating antibodies, cytokines, and autoreactive T lymphocytes are responsible for tissue injury in this autoimmune disease. The diagnosis of SLE is a rheumatological challenge despite the availability of clinical criteria. NPSLE was previously referred to as lupus cerebritis or lupus sclerosis. However, these terms are no longer recommended because there is no definitive pathological cause for the neuropsychiatric manifestations of SLE. Currently, the treatment options are primarily based on symptomatic presentations. These include the use of antipsychotics, antidepressants, and anxiolytic medications for the treatment of psychiatric and mood disorders. Antiepileptic drugs to treat seizures, and immunosuppressants (e.g., corticosteroids, azathioprine, and mycophenolate mofetil), are directed against inflammatory responses along with non-pharmacological interventions.

chemistry, multidisciplinary,biochemistry & molecular biology
Association between organ damage and mortality in systemic lupus erythematosus: a systematic review and meta-analysis

Irene B Murimi-Worstell,Dora H Lin,Henk Nab,Hong J Kan,Oluwadamilola Onasanya,Jonothan C Tierce,Xia Wang,Barnabas Desta,G Caleb Alexander,Edward R Hammond

DOI: https://doi.org/10.1136/bmjopen-2019-031850

IF: 3.006

2020-05-21

BMJ Open

Abstract:Objective: At least half of patients with systemic lupus erythematosus (SLE) develop organ damage as a consequence of autoimmune disease or long-term therapeutic steroid use. This study synthesised evidence on the association between organ damage and mortality in patients with SLE. Design: Systematic review and meta-analysis. Methods: Electronic searches were performed in PubMed, Embase, Cochrane Library and Latin American and Caribbean Health Sciences Literature for observational (cohort, case-control and cross-sectional) studies published between January 2000 and February 2017. Included studies reported HRs or ORs on the association between organ damage (measured by the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI) score) and mortality. Study quality was assessed using the modified Newcastle-Ottawa assessment. Pooled HRs were obtained using the DerSimonian and Laird random-effects model. Heterogeneity was assessed using the Cochrane Q (Q) and I2 statistics. Results: The search yielded 10 420 articles, from which 21 longitudinal studies were selected. Most studies (85%) were of high quality. For 10 studies evaluating organ damage (SDI) as a continuous variable and reporting HR as a measure of association, a 1-unit increase in SDI was associated with increased mortality; pooled HR was 1.34 (95% CI: 1.24 to 1.44, p<0.001; Q p=0.027, I2=52.1%). Exclusion of one potential outlying study reduced heterogeneity with minimal impact on pooled HR (1.33 (95% CI: 1.25 to 1.42), p<0.001, Q p=0.087, I2=42.0%). The 11 remaining studies, although they could not be aggregated because of their varying patient populations and analyses, consistently demonstrated that greater SDI was associated with increased mortality. Conclusions: Organ damage in SLE is consistently associated with increased mortality across studies from various countries. Modifying the disease course with effective therapies and steroid-sparing regimens may reduce organ damage, improve outcomes and decrease mortality for patients with SLE.
Blood-based biomarkers of neuronal and glial injury in active major neuropsychiatric systemic lupus erythematosus

Ryan Kammeyer,Kimberly Chapman,Anna Furniss,Elena Hsieh,Robert Fuhlbrigge,Ekemini A. Ogbu,Susan Boackle,JoAnn Zell,Kavita V. Nair,Tyler L. Borko,Jennifer C. Cooper,Jeffrey L. Bennett,Amanda L. Piquet

DOI: https://doi.org/10.1177/09612033241272961

IF: 2.858

2024-08-18

Lupus

Abstract:Lupus, Ahead of Print. BackgroundNeuropsychiatric systemic lupus erythematosus (NPSLE) is a poorly understood and heterogeneous manifestation of SLE. Common major NPSLE syndromes include strokes, seizures, myelitis, and aseptic meningitis. Easily obtainable biomarkers are needed to assist in early diagnosis and improve outcomes for NPSLE. A frequent end-result of major syndromes is neuronal or glial injury. Blood-based neurofilament light (NfL) and glial fibrillary acidic protein (GFAP) have been utilized as markers for monitoring disease activity and/or severity in other neurodegenerative and neuroinflammatory diseases; however, they have not been evaluated in active major NPSLE.MethodsThis was a case-control study. We enrolled patients aged 12-60 years with active major NPSLE, SLE without active major NPSLE, and healthy controls. Active NPSLE was defined as being <6 months from last new or worsening neuropsychiatric symptom. Demographics, clinical data, and serum or plasma biosamples were collected.ResultsThirteen patients with active major NPSLE, 13 age/sex/kidney function matched SLE controls without active major NPSLE, and 13 age/sex matched healthy controls (mean ages 26.8, 27.3, 26.6 years) were included. 92% of each group were female. Major syndromes included stroke (5), autonomic disorder (3), demyelinating disease (2), aseptic meningitis (2), sensorimotor polyneuropathy (2), cranial neuropathy (1), seizures (1), and myelopathy (2). Mean (standard deviation) blood NfL and GFAP were 3.6 pg/ml (2.0) and 50.4 pg/ml (15.0), respectively, for the healthy controls. Compared to healthy controls, SLE without active major NPSLE had mean blood NfL and GFAP levels 1.3 pg/ml (p = .42) and 1.2 pg/ml higher (p = .53), respectively. Blood NfL was on average 17.9 pg/ml higher (95% CI: 9.2, 34.5; p < .001) and blood GFAP was on average 3.2 pg/ml higher (95% CI: 1.9, 5.5; p < .001) for cases of active major NPSLE compared to SLE without active major NPSLE. In a subset of 6 patients sampled at multiple time points, blood NfL and GFAP decreased after immunotherapy.ConclusionsBlood NfL and GFAP levels are elevated in persons with SLE with active major NPSLE compared to disease matched controls and may lower after immunotherapy initiation. Larger and longitudinal studies are needed to ascertain their utility in a clinical setting.

rheumatology
Nervous System Disease in Systemic Lupus Erythematosus: Current Status and Future Directions

John G Hanly,Elizabeth Kozora,Steven D Beyea,Julius Birnbaum,John G. Hanly,Steven D. Beyea

DOI: https://doi.org/10.1002/art.40591

2018-11-24

Abstract:The American College of Rheumatology's case definitions for 19 neuropsychiatric syndromes in systemic lupus erythematosus (SLE) constitute a comprehensive classification of nervous system events in this disease. However, additional strategies are needed to determine whether a neuropsychiatric syndrome is attributable to SLE versus a competing comorbidity. Cognitive function is a clinical surrogate of overall brain health, with applications in both diagnosis and determination of clinical outcomes. Ischemic and inflammatory mechanisms are both key components of the immunopathogenesis of neuropsychiatric SLE (NPSLE), including abnormalities of the blood-brain barrier and autoantibody-mediated production of proinflammatory cytokines. Advances in neuroimaging provide a platform to assess novel disease mechanisms in a noninvasive way. The convergence of more rigorous clinical characterization, validation of biomarkers, and brain neuroimaging provides opportunities to determine the efficacy of novel targeted therapies in the treatment of NPSLE.

rheumatology
Neuropsychiatric symptoms in Systemic Lupus Erythematosus: mixed methods analysis of patient-derived attributional evidence in the international INSPIRE project

Melanie Sloan,Thomas A Pollak,Efthalia Massou,Guy Leschziner,Laura Andreoli,Rupert Harwood,Michael Bosley,Mervi Pitkanen,Wendy Diment,Alessandra Bortoluzzi,Michael S Zandi,Mandeep Ubhi,Caroline Gordon,David Jayne,Felix Naughton,Colette Barrere,Chris Wincup,James Brimicombe,James A Bourgeois,David D’Cruz

DOI: https://doi.org/10.1093/rheumatology/keae194

2024-03-22

Rheumatology

Abstract:Abstract Objective Attribution of neuropsychiatric symptoms in systemic lupus erythematosus (SLE) relies heavily on clinician assessment. Limited clinic time, variable knowledge, and symptom under-reporting contributes to discordance between clinician assessments and patient symptoms. We obtained attributional data directly from patients and clinicians in order to estimate and compare potential levels of direct attribution to SLE of multiple neuropsychiatric symptoms using different patient-derived measures. Methods Quantitative and qualitative data analysed included: prevalence and frequency of neuropsychiatric symptoms, response to corticosteroids, and concurrence of neuropsychiatric symptoms with non-neuropsychiatric SLE disease activity. SLE patients were also compared with controls and inflammatory arthritis (IA) patients to explore attributability of neuropsychiatric symptoms to the direct disease effects on the brain/nervous system. Results We recruited 2,817 participants, including 400 clinicians. SLE patients (n = 609) reported significantly higher prevalences of neuropsychiatric symptoms than controls (n = 463) and IA patients (n = 489). SLE and IA patients’ quantitative data demonstrated multiple neuropsychiatric symptoms relapsing/remitting with other disease symptoms such as joint pain. Over 45% of SLE patients reported resolution/improvement of fatigue, positive sensory symptoms, severe headache, and cognitive dysfunction with corticosteroids. Evidence of direct attributability in SLE was highest for hallucinations and severe headache. SLE patients had greater reported improvement from corticosteroids (p= 0.008), and greater relapsing-remitting with disease activity (p< 0.001) in the comparisons with IA patients for severe headache. Clinician and patients reported insufficient time to discuss patient-reported attributional evidence. Symptoms viewed as indirectly related/non-attributable were often less prioritised for discussion and treatment. Conclusion We found evidence indicating varying levels of direct attributability of both common and previously unexplored neuropsychiatric symptoms in SLE patients, with hallucinations and severe headache assessed as the most directly attributable. There may also be—currently under-estimated—direct effects on the nervous system in IA and other systemic rheumatological diseases.

rheumatology
Recent advances in the diagnosis and management of neuropsychiatric lupus

Alexandra C. Legge,John G. Hanly

DOI: https://doi.org/10.1038/s41584-024-01163-z

IF: 32.286

2024-10-03

Nature Reviews Rheumatology

Abstract:Neuropsychiatric manifestations of systemic lupus erythematosus (SLE) are common and frequently associated with a substantial negative impact on health outcomes. The pathogenesis of neuropsychiatric SLE (NPSLE) remains largely unknown, but a single pathogenic mechanism is unlikely to be responsible for the heterogeneous array of clinical manifestations, and a combination of inflammatory and ischaemic mechanistic pathways have been implicated. Currently, valid and reliable biomarkers for the diagnosis of NPSLE are lacking, and differentiating NPSLE from nervous system dysfunction not caused by SLE remains a major challenge for clinicians. However, correct attribution is essential to ensure timely institution of appropriate treatment. In the absence of randomized clinical trials on NPSLE, current treatment strategies are derived from clinical experience with different therapeutic modalities and their efficacy in the management of other manifestations of SLE or of neuropsychiatric disease in non-SLE populations. This Review describes recent advances in the understanding of NPSLE that can inform diagnosis and management, as well as unanswered questions that necessitate further research.

rheumatology
An evaluation of costs associated with overall organ damage in patients with systemic lupus erythematosus in the United States

Christopher F Bell,Mayank R Ajmera,Juliana Meyers

DOI: https://doi.org/10.1177/09612033211073670

IF: 2.858

2022-01-21

Lupus

Abstract:Introduction Approximately 33–50% of patients with systemic lupus erythematosus (SLE) develop organ damage within 5 years of diagnosis. Real-world studies that capture the healthcare resource utilization (HCRU) and costs associated with SLE-related organ damage are limited. The aim of this study was to evaluate HCRU and costs associated with organ damage in patients with SLE in the USA. Methods This retrospective study (GSK study 208380) used the PharMetrics Plus administrative claims database from 1 January 2008 to 30 June 2019. Patients with SLE and organ damage were identified using International Classification of Diseases (ICD)-9/10 codes derived from the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index. The first observed diagnosis of organ damage was designated as the index date. Selection criteria included: ≥18 years of age; ≥1 inpatient or ≥2 outpatient claims for SLE (≥30 days apart before the index date; ICD-9: 710.0 or ICD-10: M32, excluding M32.0); ≥1 inpatient or ≥3 outpatient claims for organ damage within 6 months for the same organ system code; continuous enrollment of 12 months both pre- and post-index date. The proportion of patients with new organ damage, disease severity, SLE flares, SLE-related medication patterns, HCRU and all-cause costs (2018 US$) were assessed 12 months pre- and post-index date. Results Of the 360,803 patients with a diagnosis of SLE, 8952 patients met the inclusion criteria for the presence of new organ damage. Mean (standard deviation (SD)) age was 46.4 (12.2) years and 92% of patients were female. The most common sites of organ damage were neuropsychiatric (22.0%), ocular (12.9%), and cardiovascular (11.4%). Disease severity and proportion of moderate/severe flare episodes significantly increased from pre- to post-index date (p < 0.0001). Overall, SLE-related medication patterns were similar pre- versus post-index date. Inpatient, emergency department and outpatient claims increased from pre- to post-index date and mean (SD) all-cause costs were 71% higher post- versus pre-index date ($26,998 [57,982] vs $15,746 [29,637], respectively). Conclusions: The economic impact associated with organ damage in patients with SLE is profound and reducing or preventing organ damage will be pivotal in alleviating the burden for patients and healthcare providers.

rheumatology
Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study

John G. Hanly,Qiuju Li,Li Su,Murray B. Urowitz,Caroline Gordon,Sang‐Cheol Bae,Juanita Romero‐Diaz,Jorge Sanchez‐Guerrero,Sasha Bernatsky,Ann E. Clarke,Daniel J. Wallace,David A. Isenberg,Anisur Rahman,Joan T. Merrill,Paul Fortin,Dafna D. Gladman,Ian N. Bruce,Michelle Petri,Ellen M. Ginzler,M. A. Dooley,Kristjan Steinsson,Rosalind Ramsey‐Goldman,Asad A. Zoma,Susan Manzi,Ola Nived,Andreas Jonsen,Munther A. Khamashta,Graciela S. Alarcón,Winn Chatham,Ronald F. Vollenhoven,Cynthia Aranow,Meggan Mackay,Guillermo Ruiz‐Irastorza,Manuel Ramos‐Casals,S. Sam Lim,Murat Inanc,Kenneth C. Kalunian,Soren Jacobsen,Christine A. Peschken,Diane L. Kamen,Anca Askanase,Chris Theriault,Vernon Farewell,Sang-Cheol Bae,Juanita Romero-Diaz,Jorge Sanchez-Guerrero,Rosalind Ramsey-Goldman,Ronald F. van Vollenhoven,Guillermo Ruiz-Irastorza,Manuel Ramos-Casals

DOI: https://doi.org/10.1002/acr.23509

2018-09-01

Abstract:OBJECTIVE: To determine the frequency, characteristics, and outcomes of cerebrovascular events (CerVEs), as well as clinical and autoantibody associations in a multiethnic/racial inception cohort of patients with systemic lupus erythematosus (SLE).METHODS: A total of 1,826 patients were assessed annually for 19 neuropsychiatric (NP) events, including 5 types of CerVEs: 1) stroke, 2) transient ischemia, 3) chronic multifocal ischemia, 4) subarachnoid/intracranial hemorrhage, and 5) sinus thrombosis. Global disease activity (Systemic Lupus Erythematosus Disease [SLE] Activity Index 2000), damage scores (SLE International Collaborating Clinics/American College of Rheumatology Damage Index), and Short Form 36 (SF-36) scores were collected. Time to event, linear and logistic regressions, and multistate models were used as appropriate.RESULTS: CerVEs were the fourth most frequent NP event: 82 of 1,826 patients had 109 events; of these events, 103 were attributed to SLE, and 44 were identified at the time of enrollment. The predominant events were stroke (60 of 109 patients) and transient ischemia (28 of 109 patients). CerVEs were associated with other NP events attributed to SLE, non-SLE-attributed NP events, African ancestry (at US SLICC sites), and increased organ damage scores. Lupus anticoagulant increased the risk of first stroke and sinus thrombosis and transient ischemic attack. Physician assessment indicated resolution or improvement in the majority of patients, but patients reported sustained reduction in SF-36 summary and subscale scores following a CerVE.CONCLUSION: CerVEs, the fourth most frequent NP event in SLE, are usually attributable to lupus. In contrast to good physician-reported outcomes, patients reported a sustained reduction in health-related quality of life following a CerVE.

rheumatology
Damage in a large systemic lupus erythematosus cohort from the Spanish Society of Rheumatology Lupus Registry (RELESSER) with emphasis on the cardiovascular system: a longitudinal analysis

Irene Altabás-González,Iñigo Rua-Figueroa,Coral Mouriño,Karen Roberts,Norman Jimenez,Julia Martinez-Barrio,María Galindo,Jaime Calvo Alén,Victor Del Campo Pérez,Esther Uriarte Itzazelaia,Eva Tomero,Mercedes Freire-González,Víctor Martínez Taboada,Eva Salgado,Paloma Vela,Antonio Fernandez-Nebro,Alejandro Olivé,Javier Narváez,Raúl Menor-Almagro,Gregorio Santos Soler,José Ángel Hernández-Beriain,Javier Manero,Elena Aurrecoechea,Oihane Ibarguengoitia-Barrena,Carlos Montilla,Gema Bonilla,Vicenç Torrente-Segarra,Ana Paula Cacheda,María Jesús García-Villanueva,Claudia Moriano-Morales,Concepción Fito Manteca,Nuria Lozano-Rivas,Cristina Bohórquez,José M Pego-Reigosa

DOI: https://doi.org/10.1136/lupus-2023-001064

2024-08-03

Abstract:Objective: To assess organ damage, with emphasis on the cardiovascular system, over the different stages of the disease in a large SLE cohort. Methods: Multicentre, longitudinal study of a cohort of 4219 patients with SLE enrolled in the Spanish Society of Rheumatology Lupus Registry. Organ damage was ascertained using the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). We longitudinally analysed SDI (globally and for each domain) over time only in the 1274 patients whose dates of damage events had been recorded. Results: During the first year after diagnosis of SLE, 20% of the 1274 patients presented with new damage manifestations. At years 2 and 3, new damage was recorded in 11% and 9% of patients. The annual percentage of patients with new damage after year 5 decreased to 5%. In the first year with the disease, most damage was accumulated in the musculoskeletal, neuropsychiatric and renal systems; in later stages, most damage was in the musculoskeletal, ocular and cardiovascular systems. Considering 'cerebrovascular accident' and 'claudication for 6 months' as cardiovascular items, the cardiovascular system was the second most affected system during the early stages of SLE, with 19% of the patients who presented with damage affected at first year after diagnosis. During the late stages, 20-25% of the patients presenting with new damage did so in this modified cardiovascular domain of the SDI. Conclusions: New damage occurs mainly during the first year following diagnosis of SLE. Cardiovascular damage is relevant in both the early and the late stages of the disease. Strategies to prevent cardiovascular damage should be implemented early after diagnosis of SLE.
The influence of intrathecal injection of methotrexate and dexamethasone on neuropsychiatric systemic lupus erythematosus (NPSLE): a retrospective cohort study of 386 patients with NPSLE

Yuxue Nie,Boyuan Sun,Xin He,Minmin Zheng,Di Wu,Yunjiao Yang,Li Zhang,Wei Bai,Nan Jiang,Lin Qiao,Can Huang,Shuang Zhou,Jiaxin Zhou,Linyi Peng,Jingwen Niu,Mengtao Li,Yan Zhao,Xiaofeng Zeng,Li Wang,Wen Zhang

DOI: https://doi.org/10.1186/s13075-023-03030-w

2023-03-28

Abstract:Background: Neuropsychiatric involvement is one of the major concerns in systemic lupus erythematosus (SLE). The therapeutic effect of intrathecal treatment of methotrexate and dexamethasone has been investigated in some exploratory studies, but its influence on the long-term prognosis of neuropsychiatric SLE (NPSLE) remains unknown. Methods: This was a propensity score-matched retrospective study. Outcomes at discharge and time free from NPSLE relapse or death were evaluated by multivariate logistic regression, survival analysis, and Cox regression as appropriate. Results: Among 386 hospitalized patients with NPSLE, the median [IQR] age was 30.0 [23.0-40.0] years, and 342 patients (88.4%) were female. Of those, 194 patients received intrathecal treatment. Patients in the intrathecal treatment group had higher Systemic Lupus Erythematosus Disease Activity Index 2000 scores (median 17 vs. 14 points, IQR 12-22 vs. 10-19 points, P <0 .001) and were more likely to receive methylprednisolone pulse therapy (71.6% vs. 49.5%, P < 0.001) than those who did not receive intrathecal therapy. Intrathecal treatment was associated with a higher probability of survival and being free from NPSLE relapse than control treatment among the 386 unmatched patients (P =0.042 by log-rank test) and within 147 propensity score-matched pairs (P =0.032 by log-rank test). In the subgroup of NPSLE patients with increased levels of protein in cerebrospinal fluid, intrathecal treatment had a positive influence on their prognosis (P < 0.001). Conclusions: Intrathecal treatment of methotrexate and dexamethasone was associated with a more favorable prognosis of NPSLE and may serve as a valuable additional therapy for NPSLE patients, especially for those with elevated levels of protein in cerebrospinal fluid.
Predictive factors of psychiatric syndrome in patients with systemic lupus erythematosus

Wenqi Geng,Shangzhu Zhang,Jinya Cao,Xia Hong,Yanping Duan,Yinan Jiang,Jing Wei

DOI: https://doi.org/10.3389/fimmu.2024.1323209

IF: 7.3

2024-03-22

Frontiers in Immunology

Abstract:Introduction: Early detection of neuropsychiatric systemic lupus erythematosus (NPSLE) remains a challenge in clinical settings. Previous studies have found different autoantibodies as markers for NPSLE. This study aimed to describe the distribution of psychiatric syndromes in a group of patients with systemic lupus erythematosus (SLE) and to investigate the association between psychiatric syndromes and specific autoantibodies. Methods: This retrospective study was conducted at a single medical center in China. We reviewed medical records of hospitalized patients with SLE who were consulted by psychiatrists due to potential mental disorders. Results of serum autoantibodies and general laboratory tests were collected. The correlation between clinical variables was examined. Binary logistic regression analyses were used to determine factors related to NPSLE and different psychiatric diagnoses. Results: Among the 171 psychiatric manifestations in 160 patients, 141 (82.4%) were attributed to SLE. Acute confusional state (ACS) had the highest prevalence (57.4%). Anti-cardiolipin (ACL) antibody ( X 2 = 142.261, p < 0.001) and anti-β2 glycoprotein I (-β2GP1) antibody ( X 2 = 139.818, p < 0.001) varied significantly between groups, with the highest positive rate found in patients with mood disorders (27.3% and 18.2%). SLE disease activity index – 2000 (SLEDAI-2K) score excluding item ACS and item psychosis was a predictor of NPSLE (OR 1.172 [95% CI 1.105 - 1.243]). Conclusions: Disease activity reflected by SLEDAI-2K score is a predictor for NPSLE. Antiphospholipid antibodies are associated with mood disorders in SLE. Further separate investigation of neuropsychiatric disorders is needed in order to better comprehend NPSLE's pathological mechanism.

immunology

Regulation of glucose utilization in tumors by a stress-modified insulin: anti-insulin system.

[The Clinical Significance of Hematological Damage in Systemic Lupus Erythematosus and Related Antibodies].

Non-simple genus minimizers in lens spaces

Patients with neuropsychiatric involvement systemic lupus erythematosus experience poorer health-related quality of life and more fatigue than systemic lupus erythematosus patients with no neuropsychiatric involvement, irrespective of neuropsychiatric activity

Prospective Study of Neuropsychiatric Events in Systemic Lupus Erythematosus

Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study

THU0036 Discriminating Central Nervous System Infection and Neuropsychiatric Involvement in Patients with Systemic Lupus Erythematosus: A Single-Center Experience

Neuropsychiatric manifestations in patients with systemic lupus erythematosus: epidemiology and radiology pointing to an immune-mediated cause

Therapeutic Strategies and Outcomes in Neuropsychiatric Systemic Lupus Erythematosus: An International Multicenter Retrospective Study

Prevalence, outcome and prognostic factors of neuropsychiatric systemic lupus erythematosus: A real world single center study

Neuropsychiatric Systemic Lupus Erythematosus: Molecules Involved in Its Imunopathogenesis, Clinical Features, and Treatment

Association between organ damage and mortality in systemic lupus erythematosus: a systematic review and meta-analysis

Blood-based biomarkers of neuronal and glial injury in active major neuropsychiatric systemic lupus erythematosus

Nervous System Disease in Systemic Lupus Erythematosus: Current Status and Future Directions

Neuropsychiatric symptoms in Systemic Lupus Erythematosus: mixed methods analysis of patient-derived attributional evidence in the international INSPIRE project

Recent advances in the diagnosis and management of neuropsychiatric lupus

An evaluation of costs associated with overall organ damage in patients with systemic lupus erythematosus in the United States

Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study

Damage in a large systemic lupus erythematosus cohort from the Spanish Society of Rheumatology Lupus Registry (RELESSER) with emphasis on the cardiovascular system: a longitudinal analysis

The influence of intrathecal injection of methotrexate and dexamethasone on neuropsychiatric systemic lupus erythematosus (NPSLE): a retrospective cohort study of 386 patients with NPSLE

Predictive factors of psychiatric syndrome in patients with systemic lupus erythematosus